Oncotelic Therapeutics Inc. is advancing next-generation drug delivery technology with its Deciparticle platform, a scalable nanotechnology system that could reshape treatment approaches in immunology and oncology. Recent data presented at the 2025 San Antonio Breast Cancer Symposium indicates the platform can package difficult-to-deliver, water-resistant drugs into uniform nanoparticles small enough for safe intravenous administration.
The platform demonstrated compatibility across multiple therapeutic categories, successfully forming stable, monodisperse particles with all five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor), and umirolimus. This capability is significant because these drugs have historically presented delivery challenges due to their chemical properties. The technology also handled tacrolimus, a key immunosuppressant drug, creating stable nanoparticles with diameters under 20 nanometers.
Beyond small molecules, the Deciparticle platform successfully packaged complex peptides including exenatide and cyclosporine A, demonstrating versatility with both linear and cyclic peptide structures. This broad compatibility suggests the platform could address delivery challenges across multiple drug classes, potentially improving efficacy and safety profiles for existing medications. The full research findings are available at https://ibn.fm/Vq9CP.
For investors tracking Oncotelic's progress, the company maintains a newsroom at https://ibn.fm/OTLC where updates are regularly posted. The implications of this technology extend beyond Oncotelic's internal pipeline, as the company's CEO, Dr. Vuong Trieu, has filed over 150 patent applications and holds 39 issued U.S. patents, contributing to a robust intellectual property portfolio.
The Deciparticle platform's ability to transform challenging drugs into deliverable nanoparticles could accelerate development timelines for new treatments while potentially improving outcomes for patients with difficult-to-treat cancers and immunological conditions. As the platform demonstrates compatibility with both established drugs and novel compounds, it may enable repurposing of existing medications with previously insurmountable delivery limitations.
This advancement comes as Oncotelic maintains strategic partnerships, including a 45% ownership stake in GMP Bio, a joint venture advancing complementary drug candidates. The company's focus on high-unmet-need cancers and rare pediatric indications positions its technology to address areas where conventional delivery methods have fallen short, potentially offering new hope for patient populations with limited treatment options.
